vimarsana.com
Home
Live Updates
Evam Carmona - Breaking News
Pages:
Latest Breaking News On - Evam carmona - Page 1 : vimarsana.com
Once-Promising Drug for Idiopathic Pulmonary Fibrosis Fails in Phase III Trial
An open-label extension trial of pamrevlumab was cancelled due to these results
San diego
United states
Mayo clinic in rochester
Victore ortega
Evam carmona
Randy dotinga
Ganesh raghu
University of washington
American thoracic society
Mayo clinic
When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis | Pulmonary Medicine | JAMA
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease that inevitably results in respiratory failure and death within 3 to 5 years of
Evam carmona
Division of pulmonary
National institutes of health
Department of internal medicine
Blood institute
Drug administration
Prone precise asthma network
Boehringer ingelheim
Computer aided lung informatics
Pathology evaluation
Precision interventions
Asthma network
Internal medicine
Critical care medicine
Mayo clinic
Interest disclosures
vimarsana © 2020. All Rights Reserved.